Comprehensive Clinical Guide: Bioresorbable Vascular Scaffolds (BVS) in Percutaneous Coronary Intervention

1. Introduction and Overview

Percutaneous Coronary Intervention (PCI) has evolved significantly since the inception of balloon angioplasty. The transition from bare-metal stents (BMS) to drug-eluting stents (DES) represented a paradigm shift in managing coronary artery disease (CAD). However, the permanent presence of a metallic scaffold in the coronary artery can lead to long-term limitations, including chronic inflammation, late-stent thrombosis, and impairment of vasomotor function.

The Bioresorbable Vascular Scaffold (BVS) was developed to provide temporary vessel support and drug delivery, eventually disappearing from the coronary wall. This "leave nothing behind" philosophy aims to restore natural vasomotion, allow for late lumen gain, and facilitate future surgical interventions if necessary. This guide provides a clinical deep-dive into the mechanism, application, and post-procedural management of BVS technology.

2. Technical Specifications and Mechanisms

Unlike traditional metallic stents (cobalt-chromium or platinum-chromium), BVS are typically engineered from biodegradable polymers, most commonly Poly-L-Lactide (PLLA).

The Mechanism of Action

The BVS functions through a three-phase lifecycle:
1. Support Phase: The scaffold provides mechanical radial support to the vessel wall, preventing recoil and maintaining lumen patency immediately following balloon angioplasty.
2. Elution Phase: The scaffold is coated with an anti-proliferative agent (typically Everolimus) to mitigate neointimal hyperplasia, similar to a DES.
3. Resorption Phase: Through hydrolysis, the polymer is broken down into lactic acid, which is eventually metabolized into water and carbon dioxide via the Krebs cycle. This process typically occurs over 24 to 36 months.

Technical Comparison Table

3. Clinical Indications and Usage

BVS is indicated for patients with symptomatic coronary artery disease due to de novo native coronary artery lesions.

Ideal Patient Profiles

• Younger Patients: Patients with longer life expectancies who may benefit from the absence of a permanent metallic implant.
• Focal Lesions: Simple, de novo lesions in vessels with favorable diameters (usually 2.5mm – 4.0mm).
• Patients with Future Surgical Risk: Those who may require future coronary artery bypass grafting (CABG) in the same vessel segment.

Pre-Procedural Preparation

1. Dual Antiplatelet Therapy (DAPT): Initiation of aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) prior to the procedure.
2. Angiographic Assessment: Quantitative Coronary Angiography (QCA) or Intravascular Ultrasound (IVUS) to ensure vessel diameter matches the scaffold size.
3. Lesion Preparation: CRITICAL. BVS requires meticulous lesion preparation. Pre-dilation with a balloon slightly smaller than the vessel size is mandatory to ensure appropriate scaffold expansion.

4. The Procedure: Step-by-Step Intervention

The implantation of a BVS follows the "PSP" protocol to maximize success and minimize the risk of scaffold thrombosis.

• P – Pre-dilation: Using a non-compliant balloon to ensure the lesion is adequately expanded before the scaffold is deployed.
• S – Sizing: Proper selection of the scaffold based on distal and proximal vessel reference diameters.
• P – Post-dilation: Utilizing a high-pressure, non-compliant balloon (larger than the scaffold diameter) to ensure the struts are fully apposed to the vessel wall.

Procedural Steps:
1. Access: Radial or femoral arterial access via standard sheath placement.
2. Imaging: Baseline angiography to identify the lesion.
3. Preparation: Pre-dilation performed using a balloon-to-artery ratio of 1:1.
4. Deployment: The BVS is advanced to the lesion site and deployed at a slow, controlled inflation rate to prevent recoil.
5. Optimization: Post-dilation is mandatory to ensure complete expansion and apposition.
6. Final Assessment: Angiographic review to ensure no edge dissections or residual stenosis.

5. Post-Op Recovery and Long-Term Protocol

Recovery from BVS-PCI is similar to traditional stenting, but requires strict adherence to medication regimens.

• Immediate Post-Op: Monitoring at the sheath site for hematoma; ECG monitoring for 4–6 hours.
• DAPT Duration: Because of the thicker struts, prolonged DAPT (minimum 12 months) is generally recommended to prevent late scaffold thrombosis.
• Lifestyle Modifications: Smoking cessation, lipid management (statin therapy), and blood pressure control remain the pillars of secondary prevention.

6. Risks, Side Effects, and Contraindications

Contraindications

• Small Vessels: Vessels < 2.5mm are generally contraindicated due to the risk of scaffold thrombosis.
• Severely Calcified Lesions: Heavy calcification may prevent proper expansion, leading to malapposition.
• Allergy: Known hypersensitivity to the polymer (PLLA) or the anti-proliferative drug (Everolimus).

Potential Complications

• Scaffold Thrombosis: The most significant concern, particularly in the first 30 days and late stages (beyond 1 year).
• Edge Dissection: Occurs if the scaffold is undersized or improperly placed.
• Restenosis: While rare, it can occur due to incomplete expansion.

7. Frequently Asked Questions (FAQ)

1. How long does the scaffold stay in the artery?
The scaffold provides support for approximately 6–12 months, with full resorption typically occurring within 24–36 months.

2. Is BVS better than a metal stent?
BVS offers the advantage of restoring vessel function, but current clinical data suggests that in complex lesions, metallic DES may have a more favorable safety profile.

3. Can I have an MRI after BVS placement?
Yes. Because the scaffold resorbs and is non-ferromagnetic, it is generally MRI-safe after the resorption process is complete.

4. What happens if the scaffold breaks?
Minor fractures can occur during the resorption process, but these are generally benign as the polymer fragments are absorbed by the body.

5. What is the biggest risk with BVS?
The primary risk is scaffold thrombosis, which is why strict adherence to DAPT is mandatory.

6. Can BVS be used in emergency heart attack (STEMI) cases?
While technically possible, it is generally reserved for stable CAD or non-complex acute cases due to the stringent pre-dilation requirements.

7. Is the procedure more expensive than standard PCI?
Yes, BVS technology is typically more expensive than standard drug-eluting stents due to the complex manufacturing process.

8. What if I need another procedure later?
Because the scaffold disappears, the vessel segment remains "clean," allowing for future surgical grafting (CABG) or repeat PCI if necessary.

9. Why is "post-dilation" so important?
BVS struts are thicker than metal stents. If they are not perfectly apposed to the wall, they can disrupt blood flow and lead to clotting.

10. How do doctors know if the scaffold has resorbed?
Resorption can be monitored via Optical Coherence Tomography (OCT), which provides high-resolution imaging of the vessel wall.

8. Alternative Treatments

While BVS is an innovative approach, clinicians must consider alternatives based on patient anatomy:
* Drug-Eluting Stents (DES): The current gold standard for most PCI procedures, offering thinner struts and proven long-term outcomes.
* Drug-Coated Balloons (DCB): Used primarily for in-stent restenosis or small vessel disease where stenting is undesirable.
* Coronary Artery Bypass Grafting (CABG): The preferred treatment for complex, multi-vessel disease, particularly in patients with diabetes or high-grade left main stenosis.

9. Conclusion

Bioresorbable Vascular Scaffolds represent a sophisticated leap toward physiological vascular restoration. By eliminating the "permanent cage" of metallic stents, they offer unique benefits for specific patient populations. However, the success of BVS is highly dependent on operator technique—specifically the adherence to the PSP (Pre-dilation, Sizing, Post-dilation) protocol. As technology advances and strut thickness decreases, BVS may eventually become a standard of care, but for now, it remains a specialized tool requiring careful patient selection and expert execution.

Disclaimer: This guide is for educational and informational purposes only and does not constitute medical advice. All PCI procedures must be performed by qualified interventional cardiologists in a clinical setting. Always consult with a medical professional regarding specific treatment plans.